List of Excipients in Branded Drug ULTANE

ULTANE Excipient Strategy and Commercial Opportunities for Sevoflurane

Last updated: August 2, 2026

ULTANE is a sevoflurane inhalation anesthetic supplied as essentially neat active pharmaceutical ingredient rather than a conventional excipient-containing formulation. Its commercial value is tied to purity, vaporizer performance, packaging compatibility, supply reliability, and operating-room procurement rather than to a differentiated excipient platform. The original brand has no meaningful remaining exclusivity barrier based on the age of its FDA approval, and competition is primarily from generic sevoflurane suppliers.

What is ULTANE and how is it formulated?

ULTANE contains sevoflurane, a volatile fluorinated ether administered through an anesthesia vaporizer. The FDA-approved product is a clear, colorless, nonflammable liquid for inhalation. The label states that ULTANE contains no additives or stabilizers [1].

Attribute	ULTANE profile
Active ingredient	Sevoflurane
Dosage form	Volatile liquid for inhalation
Route	Inhalation through an anesthesia vaporizer
Excipient content	No intentional excipients or stabilizers stated in the FDA label
Primary use	Induction and maintenance of general anesthesia
Administration system	Calibrated anesthetic vaporizer
Original FDA approval	1990s-era NDA approval
Current competitive basis	Drug purity, vaporizer compatibility, packaging, supply, and price
Main substitutes	Desflurane, isoflurane, intravenous anesthetics, generic sevoflurane

ULTANE is materially different from most pharmaceutical products because the formulation is not built around solubilizers, preservatives, buffers, surfactants, or controlled-release polymers. Sevoflurane is itself a liquid at room temperature and is vaporized before delivery to the patient.

The label identifies no conventional excipient system. The product's functional requirements are controlled by the sevoflurane molecule, container closure system, and vaporizer.

What excipients are used in ULTANE?

ULTANE's excipient strategy is a zero-excipient strategy. The product does not require:

• Preservatives
• Antioxidants
• Buffers
• Tonicity agents
• Solubilizers
• Surfactants
• Suspending agents
• Chelating agents
• Co-solvents
• Taste-masking agents

Sevoflurane is formulated and supplied as a high-purity liquid. The formulation objective is to maintain chemical stability and prevent contamination or degradation during storage and vaporization.

This approach has several commercial advantages:

1. It reduces formulation complexity.
2. It eliminates excipient-related toxicology and compatibility issues.
3. It reduces the risk of pulmonary exposure to nonactive ingredients.
4. It simplifies regulatory comparability for generic manufacturers.
5. It shifts development risk from formulation science to manufacturing control and packaging.

The absence of additives does not eliminate product-development requirements. Manufacturers must control water content, impurities, degradation products, container interaction, filling accuracy, and vaporizer delivery.

Why does ULTANE not require conventional excipients?

Sevoflurane has physical properties that support direct use as an inhaled liquid. The drug is delivered in vapor form, so the formulation does not need to disperse a solid dose, stabilize an aqueous solution, or control dissolution in the gastrointestinal tract.

Its critical product attributes include:

• Assay and purity
• Identity
• Water content
• Volatile and nonvolatile impurities
• Degradation products
• Container closure integrity
• Vaporizer compatibility
• Delivered concentration
• Storage stability

Sevoflurane can degrade in the presence of strong bases and may interact with certain absorbent materials used in anesthesia systems. The FDA labeling for ULTANE addresses compound A formation and the interaction between sevoflurane and carbon dioxide absorbents [1].

The principal formulation risk therefore concerns the drug substance and delivery environment, not the selection of excipients.

What formulation and packaging patents protect ULTANE?

ULTANE's commercial protection historically depended more heavily on sevoflurane composition, manufacturing, use, and delivery-system intellectual property than on conventional excipient patents. The original product was approved decades ago, and the principal product-level exclusivity period has expired.

A conventional excipient patent strategy is weak for ULTANE because:

• The product has no meaningful excipient package.
• Generic sevoflurane can use a comparable neat-drug formulation.
• Packaging materials are generally substitutable if performance requirements are met.
• Vaporizer compatibility is often governed by device specifications and operating standards rather than by a single brand-specific patent.
• Hospital purchasers can substitute products when FDA-approved labeling and vaporizer performance are acceptable.

Potentially relevant intellectual-property categories include:

IP category	Strategic relevance
Sevoflurane composition and synthesis	Historically important; likely expired or commercially weak for current U.S. entry
Purification processes	Can create manufacturing advantages, but may be difficult to enforce against finished-product competitors
Impurity-control methods	Relevant to quality differentiation and regulatory approval
Container closure systems	May protect packaging configurations, but generally offer limited blocking power
Anesthesia vaporizer systems	Potentially valuable, but usually separate from the drug product
Carbon dioxide absorbent systems	Relevant to degradation-product control and anesthesia safety
Method-of-use claims	Potentially relevant to anesthesia protocols, but vulnerable to labeling and infringement limitations
Supply-chain and manufacturing know-how	Often more commercially important than published patents

A current freedom-to-operate review would need to distinguish expired sevoflurane patents from active patents covering packaging, manufacturing equipment, vaporizer hardware, absorbent materials, and hospital administration systems. No single active excipient patent appears to define ULTANE's commercial position.

When did ULTANE lose exclusivity?

ULTANE's original U.S. market exclusivity and core patent protection are no longer the principal barriers to competition. Sevoflurane is available from multiple manufacturers and has generic regulatory pathways.

The relevant exclusivity structure is:

Exclusivity or protection	Current commercial effect
Original NDA exclusivity	Expired
Core composition protection	Expired or commercially exhausted
Pediatric exclusivity	No current blocking effect identified for ULTANE
Orphan exclusivity	Not applicable
Biosimilar exclusivity	Not applicable because sevoflurane is a small molecule
Orange Book patent block	No current ULTANE-specific barrier is generally understood to prevent generic entry
Formulation exclusivity	Limited because the product contains no differentiated excipient system

The FDA Orange Book remains the primary source for current patent-listing and exclusivity information associated with NDA 020475. Sevoflurane products are regulated as small-molecule drugs, so applicants generally use the ANDA pathway rather than the biosimilar pathway [2].

What is the Orange Book status of ULTANE?

ULTANE is associated with an FDA-approved new drug application for sevoflurane inhalation. The practical Orange Book question is whether any unexpired, listed patent blocks an ANDA applicant.

For a product of ULTANE's age, the competitive assessment should focus on:

• Whether the reference listed drug remains designated as the applicable reference product.
• Whether any patent listings remain unexpired.
• Whether listed patents cover the drug substance, product, or method of use.
• Whether generic applicants have made Paragraph IV certifications.
• Whether litigation triggered a 30-month stay.
• Whether an authorized generic or licensing arrangement affects launch economics.

Because sevoflurane has been commercially available for many years from multiple suppliers, the risk of a new, brand-controlled formulation barrier is low. Current competition is more likely to involve supply contracts, manufacturing capacity, and regulatory execution than Orange Book litigation.

Have generic manufacturers challenged ULTANE under Paragraph IV?

Sevoflurane has a mature generic market, and generic applicants have used ANDA pathways where applicable. Publicly visible Paragraph IV activity is less commercially significant today than it would have been during the initial loss-of-exclusivity period.

A Paragraph IV analysis should distinguish between:

• Historical challenges to original ULTANE patents.
• Later ANDAs filed after core patents expired.
• Patent litigation involving sevoflurane manufacturing or labeling.
• Administrative or regulatory disputes unrelated to patent validity.
• Commercial launches by suppliers that entered after patent expiry.

For current investment analysis, the key point is that ULTANE does not have the profile of a protected, single-source branded product. Generic entry has already occurred, and Paragraph IV activity is not the principal current risk to the brand.

What commercial opportunities exist in ULTANE's excipient strategy?

The strongest opportunities do not involve adding excipients to ULTANE. Adding a stabilizer, preservative, or co-solvent could increase regulatory and toxicological complexity without creating a clear clinical benefit.

More attractive opportunities include:

Higher-purity sevoflurane

A supplier can compete through tighter impurity specifications, validated control of degradation products, and consistent performance across anesthesia machines. This strategy supports premium positioning in hospitals that prioritize operating-room reliability.

Improved packaging

Packaging can create value through:

• Lower drug loss during storage
• Better protection from light and moisture
• Reduced extractables and leachables
• Improved bottle ergonomics
• Tamper evidence
• Unit-dose or controlled-volume formats
• Compatibility with automated anesthesia-system workflows

Packaging changes would need to preserve product stability and avoid introducing materials that interact with sevoflurane.

Closed-transfer systems

A closed-transfer or low-loss delivery system could reduce handling losses, occupational exposure, and waste during bottle connection and disposal. The commercial opportunity would likely be strongest if the system interoperates with major anesthesia machines without requiring hospital-wide equipment replacement.

Vaporizer-linked offerings

A supplier could combine sevoflurane with vaporizer service, calibration, inventory management, and usage monitoring. This creates a systems-level proposition that is harder to replicate than a commodity bottle alone.

Supply assurance

Sevoflurane is a hospital-critical product. Manufacturing redundancy, regional inventory, and validated alternate sites may support contracts even where unit price is not the lowest. Shortages or constrained production capacity can shift purchasing decisions toward dependable suppliers.

Lower-waste formats

Sevoflurane is volatile and can be lost through handling, storage, and disposal. Packaging designed to reduce residual volume and transfer losses could produce measurable hospital savings. The opportunity depends on demonstrating total cost reduction rather than merely offering a smaller bottle.

Sustainability initiatives

Operating-room anesthetic gases have environmental implications. A commercial strategy could address:

• Reduced manufacturing waste
• Lower packaging mass
• Improved recovery or scavenging
• Lower residual drug volume
• Transparent lifecycle data

This would be a service and packaging opportunity rather than an excipient opportunity.

What manufacturing and intellectual-property barriers affect sevoflurane?

The principal barriers are technical and operational.

Chemical manufacturing

Sevoflurane production requires control of fluorinated intermediates, reaction conditions, purification, and residual impurities. The molecule's manufacturing process is not equivalent to ordinary generic liquid filling.

Impurity control

Critical impurities may arise from raw materials, reaction byproducts, storage, or interactions with packaging. A robust control strategy must address both release specifications and stability-indicating methods.

Packaging compatibility

Sevoflurane must be stored in a container that limits leakage, maintains chemical stability, and does not contribute unacceptable extractables or leachables. Closure components require compatibility testing over the proposed shelf life.

Vaporizer performance

The product must produce a predictable delivered concentration when used with labeled vaporizers. A generic product that is chemically equivalent but operationally inconsistent would face significant hospital adoption barriers.

Regulatory CMC documentation

An ANDA applicant must demonstrate pharmaceutical equivalence and bioequivalence under the applicable FDA framework. For a volatile inhalation anesthetic, the CMC package and device-use considerations are central to approval.

How does ULTANE compare with isoflurane and desflurane?

Factor	Sevoflurane / ULTANE	Isoflurane	Desflurane
Dosage form	Volatile liquid	Volatile liquid	Volatile liquid
Excipient strategy	Neat drug, no stated additives	Neat drug, generally no excipient system	Neat drug, generally no excipient system
Induction profile	Rapid and relatively well tolerated	Slower and more pungent	Rapid
Operating-room use	Broad use for induction and maintenance	Established, often lower-cost	Rapid emergence, but higher environmental and equipment concerns
Generic competition	Mature	Mature	Mature but commercial demand has faced pressure
Key commercial differentiator	Supply, purity, vaporizer compatibility	Price and familiarity	Recovery profile, cost, environmental considerations
Excipient opportunity	Low	Low	Low
Packaging opportunity	Moderate	Moderate	Moderate
Service opportunity	High	High	High

ULTANE's strongest position is not a proprietary formulation. It is the combination of established clinical use, vaporizer infrastructure, regulatory familiarity, and hospital purchasing relationships.

What litigation and settlement risks affect ULTANE?

Current litigation risk is likely to be lower than during the original generic-entry period because the core product is mature and multiple suppliers exist. Relevant risks include:

• Patent disputes over manufacturing methods
• Trade-secret claims involving fluorinated chemistry
• Packaging and container-closure disputes
• Contract litigation over hospital or distributor supply
• Product-liability claims involving anesthesia administration
• Regulatory disputes involving impurities or manufacturing sites
• Antitrust issues tied to supply agreements or authorized-generic arrangements

A settlement agreement could affect launch timing only if it relates to a still-enforceable patent or a specific manufacturing claim. For a mature sevoflurane product, commercial settlements are more likely to concern supply, distribution, or procurement than long-term exclusivity.

What generic launch scenarios exist for ULTANE?

The likely launch scenarios are:

Commodity-price launch

A manufacturer enters with a chemically equivalent product and competes primarily on acquisition cost. This is the most direct strategy and carries margin pressure.

Premium reliability launch

A supplier charges more for validated supply continuity, tight impurity control, and dependable vaporizer performance. This strategy is more viable during shortages or for large hospital systems with high anesthesia volumes.

Integrated equipment launch

A supplier links sevoflurane sales to vaporizer service, consumables, and anesthesia-workflow support. This can increase switching costs without relying on drug patents.

Regional manufacturing launch

A local or regional producer uses domestic capacity and shorter supply routes to compete for government, group-purchasing, or strategic hospital contracts.

Low-waste packaging launch

A new container or transfer system targets lower residual volume and easier handling. Regulatory approval, compatibility testing, and workflow adoption determine the commercial outcome.

What is the revenue exposure for ULTANE?

ULTANE-specific revenue is not reliably disclosed as a separate public line item. Brand-level exposure should therefore be estimated using:

• Hospital procedure volume
• Sevoflurane consumption per procedure
• Brand versus generic share
• Contract pricing
• Geographic mix
• Distributor inventory
• Supply constraints
• Anesthesia-machine compatibility
• Use of competing inhaled and intravenous anesthetics

Revenue risk is high if the business depends on brand pricing without a differentiated service or supply proposition. Revenue resilience improves when the supplier controls manufacturing capacity, hospital contracts, distribution, or vaporizer-related services.

How strong is the ULTANE patent estate?

ULTANE's current patent estate is commercially weak compared with a recently launched drug. The product has no conventional excipient platform, no biologic exclusivity, and no obvious active formulation barrier that would prevent generic substitution.

Patent strength should be assessed across four dimensions:

Dimension	Assessment
Core molecule	Weak current blocking power because of product age
Excipient formulation	Very weak; no differentiated excipient system
Manufacturing process	Potentially relevant but difficult to use as a broad market block
Delivery system	Potentially valuable if linked to proprietary hardware or workflow

The durable moat is operational rather than patent-based.

Key Takeaways

• ULTANE is a neat sevoflurane liquid with no intentional excipients or stabilizers identified in the FDA label.
• Its formulation strategy minimizes excipient risk but leaves little room for conventional formulation patent protection.
• Sevoflurane's core exclusivity has expired, and generic competition is established.
• ULTANE's commercial differentiation depends on purity, packaging, vaporizer compatibility, supply reliability, and hospital contracts.
• The strongest new-product opportunities involve closed-transfer systems, lower-waste packaging, supply assurance, and integrated anesthesia services.
• Biosimilar risk is not applicable because sevoflurane is a small-molecule drug.
• Paragraph IV litigation and Orange Book barriers are less important today than manufacturing, procurement, and supply-chain execution.
• A premium brand strategy requires measurable operational benefits because a price premium is difficult to defend through formulation alone.

FAQs

Is ULTANE preservative-free?

Yes. The FDA label states that ULTANE contains no additives or stabilizers [1].

Can sevoflurane be reformulated with excipients?

Technically possible, but commercially unattractive unless the excipient creates a measurable safety, stability, delivery, or waste-reduction benefit. The existing product is administered as neat sevoflurane.

Is ULTANE eligible for biosimilar competition?

No. Sevoflurane is a small-molecule drug. Competitors generally use the abbreviated new drug application pathway rather than the biosimilar pathway.

What is the most defensible commercial innovation for generic sevoflurane?

The strongest opportunities are packaging, closed-transfer delivery, supply continuity, and vaporizer-linked services. A new excipient is unlikely to create sufficient value.

Does ULTANE have a meaningful formulation patent moat?

No. ULTANE's lack of a differentiated excipient system limits formulation-based exclusivity. Current competitive protection is primarily operational and commercial.

References

1. U.S. Food and Drug Administration. (2016). ULTANE (sevoflurane, USP) liquid for inhalation: Prescribing information. AbbVie Inc.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs database. https://www.accessdata.fda.gov/scripts/cder/daf/

4. American Society of Anesthesiologists. (2023). Practice guidelines and resources for inhaled anesthetic administration. https://www.asahq.org/

5. Eger, E. I. (2004). Characteristics of anesthetic agents used for induction and maintenance of general anesthesia. Anesthesiology Clinics, 22(2), 197-214.